Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction
Numerous subjective indicators from research on DSIP effects in humans suggest that the peptide does indeed promote sleep, inducing feelings of drowsiness, increasing sleep by 59% within a 130-min interval after the treatment, as compared to placebo, and shortening sleep onset as well
Statistics JMP Pro software version 15.0.0 (SAS Institute Inc., Cary, NC, USA) or GraphPad Prism7.05 was used for the statistical analysis
For specific guidance based on your formulation and pharmacy, check the label or contact your pharmacy directly
This tablet is prescribed to help lighten and reduce these dark patches, improving the overall appearance of the skin
Get started Sign up for MyBlue To get the most out of your coverage, create a MyBlue account
